JNJ · Johnson & Johnson

Track JNJ — free

$254.18 +1.25 (+0.49%)

S&P 500 member Russell 1000 member Dow 30 member Rebalance outlook locked

Market Cap

$653.61B

2.41B

Volume · Oct 5 10.03M Avg daily vol (3M) 7.09M

Up next

Next earnings call

Oct 13, 2026 Scheduled · in 1 wks

Latest filing: 10-Q

filed Jul 23, 2026

Q2 2027 earnings call transcript

call held Jul 15, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$97.93B

Trailing 12 months

Net income (TTM)

$21.04B

Trailing 12 months

Revenue growth YoY

+6.6%

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

29.7

Trailing earnings · reciprocal yield 3.4%

FCF yield

3.4%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

−$28.28B

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+0.9%

Year over year · more shares

Price change (1Y)

+37.7%

Trailing year

Short interest

0.9%

Latest settlement · 3.7 days to cover

View all 115 metrics

Equibles Research

our published analysis of this company

Research Thesis July 31, 2026

Novo Nordisk's 1.3 million Wegovy pill TRxs meet a 50% WAC cut — and the bear case still wins

Novo Nordisk is the only name in the GLP-1 bellwether set guiding negative adjusted-sales growth for 2026 (-4% to -12% at CER), even as Wegovy pill TRxs hit around 1.3 million in Q1 2026 and the 1 January 2027 WAC reset to USD 675 locks in further realised-price compression.

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Neutral Momentum Neutral Sentiment Bullish Fundamentals Excellent Quant / Vol Very Low

Market backdrop VIX 15.5 · calm Equity put/call 0.59

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +5%

above

Price vs 50-day avg −5%

below

RSI (14) 29

oversold

MACD trend Negative

52-week position 72%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Neutral

1-month return −8%

trailing

6-month return +5%

trailing

YTD return +22%

this year

Relative strength −6%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $266 › 200d $242 — 50d above 200d

Institutional flow Accumulating

49 of 4,717 funds reported for Sep 30 · net +349.8K sh shares · +1 new

Insider flow Distributing

Net -$67.8M over 90 days · 100% sells

Short interest Falling

0.88% of float · ▼ -2.2% MoM · 3.7 days cover

Volume signal Reversal watch

High volume on a down day — possible exhaustion

Institution breadth Multi-yr high

4,717 holders — near 3-yr high, broad support

Squeeze score 43

elevated · 0–100

Fundamentals

Excellent

Revenue growth +6%

Y/Y

Gross margin 68%

contracting

EPS growth +91%

Y/Y

Free cash flow $19.7B

Valuation P/E 31.5

below peers

Buyback $5.0B

authorized

Balance sheet $21.7B

net debt

Quant / Vol

risk profile

Very Low

Volatility 19%

annualized · 1-yr

Max drawdown −11%

past year

ATR 2.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 1 of last 2

Latest guidance · from the Earnings Call filed Jul 15, 2026

full year 2026

Reported earnings per share GAAP Initiated $11.60 – $11.75

prior FY $11.03 midpoint +5.8% Y/Y

full year

Effective tax rate 17% – 18%

Guided vs delivered · last 2 settled

Estimated Reported Sales 2023 full-year

guided $97.9B – $98.9B

guided $97.9B – $98.9B $85.16B Miss −13.5%

Earnings per share 2022

guided $0.20

guided $0.20 $6.73 Beat +3265.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 5 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+5% Bullish

Price vs 50-day avg

−5% Neutral

RSI (14)

29 Neutral

MACD trend

Negative Bearish

52-week position

72% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $266 › 200d $242 — 50d above 200d

Institutional flow Accumulating

49 of 4,717 funds reported for Sep 30 · net +349.8K sh shares · +1 new

Insider flow Distributing

Net -$67.8M over 90 days · 100% sells

Short interest Falling

0.88% of float · ▼ -2.2% MoM · 3.7 days cover

Volume signal Reversal watch

High volume on a down day — possible exhaustion

Institution breadth Multi-yr high

4,717 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $186 Now $253 · 72% Range high $278

vs 200-day avg +5% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Cardiovascular franchise operational sales change	3.1%	fiscal second quarter of 2026 filing	—
Dividends per share	$1.34	fiscal second quarter of 2026 filing	—
International Innovative Medicine sales change	6%	fiscal second quarter of 2026 filing	—
International MedTech sales change	5.2%	fiscal second quarter of 2026 filing	—
Net debt position	$28.2B	fiscal second quarter of 2026 filing	—
Neuroscience operational sales change	13.4%	fiscal second quarter of 2026 filing	—
Oncology operational sales change	16.1%	fiscal second quarter of 2026 filing	—
Orthopaedics franchise operational sales change	4.2%	fiscal second quarter of 2026 filing	—
Pulmonary Hypertension operational sales change	2.2%	fiscal second quarter of 2026 filing	—
Surgery franchise operational sales change	2.3%	fiscal second quarter of 2026 filing	—
U.S. Innovative Medicine sales change	8.9%	fiscal second quarter of 2026 filing	—
Vision franchise operational sales change	5.6%	fiscal second quarter of 2026 filing	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - General — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
JNJ Johnson & Johnson this stock	$653.61B	+22.2%	+6.0%	31.5	0.9%
LLY ELI LILLY & Co	$1.11T	+6.4%	+44.7%	39.7	0.8%
ABBV AbbVie Inc.	$466.80B	+16.3%	+8.6%	74.6	1.1%
MRK Merck & Co., Inc.	$367.07B	+32.6%	+1.3%	119.0	1.4%
NVS Novartis AG	$276.48B	+2.2%	—	—	0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

4,718

% held: 76.2%
Reported: 49 of 4,717
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

1,727

View

Short & Settlement

Short Interest Falling

Shares short

21.2M

Days to cover: 3.7d
Change: -482.1K sh

View

Short Volume

Short vol %

40%

As of: Oct 5, 2026

Short Total

View

Fails to Deliver

FTD shares

991

Value: $272.8K
As of: Sep 8, 2026

View

Off-Exchange

Off-exchange %

47.1%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$67.8M

Buyers / Sellers: 0 / 5

Buyers Sellers

View

Congressional Trades Sell

Member

Richard Dean McCormick

Amount: $1.0K–$15.0K
Traded: Jul 30, 2026

View

Financials

Revenue (FY)

$94.2B

Net income (FY): $26.8B
EPS diluted: $11.03

View

Buybacks

Authorized

$5.0B

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 14, 2026
This year: 16

View

Proposed Sales

Value

$9.2M

Shares: 33.6K
Filed: Sep 2, 2026

View

Earnings & Events

Webcasts Upcoming

Next webcast

Oct 13, 2026

Last webcast: Sep 14, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
JNJ	-7.0%	-8.1%	+5.3%	-4.5%	+22.2%
SPY	+1.2%	+0.6%	+11.6%	+1.6%	+13.6%
vs SPY	-8.2%	-8.7%	-6.2%	-6.1%	+8.6%

Capital returns

Buyback program · as of Sep 14, 2022

Authorized

$5.00B

Spent (derived)

—

Remaining

—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 200406 CUSIP 478160104 13F (30d) 157 filings 85 filers Visit website Investor relations

JNJ · Johnson & Johnson

Price & Indicators

Up next

Metrics snapshot

Equibles Research

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns